Skip to main navigation Skip to search Skip to main content

Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results

  • Martin Gutierrez
  • , Wei Sen Lam
  • , Matthew D. Hellmann
  • , Matthew A. Gubens
  • , Charu Aggarwal
  • , Daniel Shao Weng Tan
  • , Enriqueta Felip
  • , Joanne W.Y. Chiu
  • , Jong Seok Lee
  • , James Chih Hsin Yang
  • , Edward B. Garon
  • , Giovanna Finocchiaro
  • , Myung Ju Ahn
  • , Alexander Luft
  • , Gregory A. Landers
  • , Andrea Basso
  • , Hua Ma
  • , Julie Kobie
  • , John Palcza
  • , Razvan Cristescu
    • Lawrence Fong, Alexandra Snyder, Jianda Yuan, Roy S. Herbst
  • Rutgers - The State University of New Jersey, Newark
  • Government of Western Australia, Department of Health
  • Memorial Sloan-Kettering Cancer Center
  • AstraZeneca
  • University of California at San Francisco
  • University of Pennsylvania
  • National Cancer Centre
  • Vall d'Hebron Institute of Oncology
  • The University of Hong Kong
  • Seoul National University
  • National Taiwan University
  • University of California at Los Angeles
  • IRCCS Istituto Clinico Humanitas - Rozzano (Milano)
  • Leningrad Regional Clinical Hospital
  • The Oncology Centre
  • Merck
  • Pfizer
  • Generate Biomedicines
  • Yale University

Research output: Contribution to journal › Article › peer-review

45   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology

Neuroscience